MicroRNA expression levels as diagnostic biomarkers for intraductal papillary mucinous neoplasm
Metrics: PDF 1070 views | HTML 1854 views | ?
Lei Wang1,*, Jianming Zheng2,*, Chang Sun1,*, Li Wang3, Gang Jin4, Lei Xin1, Zhendong Jin1, Dong Wang1 and Zhaoshen Li1
1Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
2Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
3Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
4Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
*These authors have contributed equally to this study
Zhaoshen Li, email: Zhaoshenli.firstname.lastname@example.org
Keywords: intraductal papillary mucinous neoplasms (IPMNs), miRNA, cancer diagnosis
Received: January 23, 2017 Accepted: March 10, 2017 Published: May 08, 2017
Intraductal papillary mucinous neoplasms (IPMNs) are deadly exocrine mucinous tumors. Currently the molecular features and diagnostic markers of IPMNs are not well understood. In this study, we performed microRNA (miRNA) profiling assays to study the potential roles of miRNAs in IPMNs using 78 cases of IPMN patients and controls. When comparing the miRNA expression between IPMN patient samples and controls, we found that miR-210, miR-223, miR-221, miR-155 and miR-187 were differentially expressed in normal pancreas and IPMNs. We further studied the miRNA expression profiles in different pancreatic diseases and identified miRNA features that are associated with Chronic pancreatitis (CP), IPMN, and Pancreatic ductal adenocarcinoma (PDAC). Therefore, these miRNAs might serve as new risk biomarkers of IPMN and could be useful for future targeted therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.